Paradoxical thrombotic effects of aspirin: Experimental study on 1000 animals

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 2, 2010, Pages 103-110

  Doutremepuich, Christian ^a   Aguejouf, Omar ^a   Desplat, Vanessa ^a   Eizayaga, Francisco X ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Aspirin; COX selective inhibitors; Thrombosis

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; MALE; NONHUMAN; RAT; THROMBOSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG INTERACTION; SUBSTANCE WITHDRAWAL SYNDROME; TOXICITY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; NITROBENZENES; PYRAZOLES; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME; SULFONAMIDES; THROMBOSIS;

EID: 77953675822     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910791292510     Document Type: Article

References (25)

1. Antman, E.M.; Hand, M.; Armstrong, P.W.; Bates, E.R.; Green, L.A.; Halasyamani, L.K.; Hochman, J.S.; Krumholz, H.M.; Lamas, G.A.; Mullany, C.J.; Pearle, D.L.; Sloan, M.A.; Smith, S.C.; Jr, Anbe, D.T.; Kushner, F.G.; Ornato, J.P.; Pearle, D.L.; Sloan, M.A.; Jacobs, A.K.; Adams, C.D.; Anderson, J.L.; Buller, C.E.; Creager, M.A.; Ettinger, S.M.; Halperin, J.L.; Hunt, S.A.; Lytle, B.W.; Nishimura, R.; Page, R.L.; Riegel, B.; Tarkington, L.G.; Yancy, C.W. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with S T-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol, 2008, 51(2), 210-247.
2. Ferrari, E.; Benhamou, M.; Cerboni, P.; Marcel, B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol., 2005, 45(3), 456-459.
3. Fischer, L.M.; Schlienger, R.G.; Matter, C.M.; Jick, H.; Meier, C.R. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch. Intern. Med., 2004, 164(22), 2472-2476.
4. Serebruany, V.L.; Malinin, AI, Bhatt, D.L. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am. J. Med., 2006, 119(8), 707.e11-6.
5. Collet, J.P.; Montalescot, G.; Blanchet, B.; Tanguy, M.L.; Golmard, J.L.; Choussat, R.; Beygui, F.; Payot, L.; Vignolles, N.; Metzger, J.P.; Thomas, D. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation, 2004, 110(16), 2361-2367.
6. Maulaz, A.B.; Bezerra, D.C.; Michel, P.; Bogousslavsky, J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch. Neurol., 2005, 62(8), 1217-1220.
7. Sibon, I.; Orgogozo, J.M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology, 2004, 62(7), 1187-1189.
8. Albaladejo, P.; Geeraerts, T.; Francis, F.; Castier, Y.; Leseche, G.; Marty, J. Aspirin withdrawal and acute lower limb ischemia. Anesth. Analg., 2004, 99(2), 440-443.
9. Biondi-Zoccai, G.G.; Lotrionte, M.; Agostoni, P.; Abbate, A.; Fusaro, M.; Burzotta, F.; Testa, L.; Sheiban, I.; Sangiorgi, G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J., 2006, 27(22), 2667-2674.
10. Burger, W.; Chemnitius, J.M.; Kneissl, G.D.; Rucker, G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation. J. Intern. Med., 2005, 257(5), 399-414.
11. Eisenberg, M.J.; Richard, P.R.; Libersan, D.; Filion, K.B. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation, 2009, 119(12), 1634-1642.
12. Aguejouf, O.; Belougne-Malfatti, E.; Doutremepuich, F.; Belon, P.; Doutremepuich, C. Thrombo-embolic complications several days after a single-dose administration of aspirin. Thromb. Res., 1998, 89(3), 123-127.
13. Vesvres, M.H.; Doutremepuich, F.; Lalanne, M.C.; Doutremepuich, C. Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis, 1993, 23, 8-12.
14. Smith, C.J.; Zhang, Y.; Koboldt, C.M. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA, 1998, 95, 13313-13318.
15. Brenneis, C.; Maier, T.J.; Schmidt, R.; Hofacker, A.; Zulauf, L.; Jakobsson, P.J.; Scholich, K.; Geisslinger, G. Inhibition of prostag-landin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEBJ, 2006, 20(9), 1352-1360.
16. Barnett, J.; Chow, J.; Ives, D.; Chiou, M.; Mackenzie, R.; Osen, E.; Nguyen, B.; Tsing, S.; Bach, C.; Freire, J. Purification, characterization and selective inhibition of human prostaglandin G/H synthase and 2 expressed in the baculovirus system. Biochim. Biophys. Acta, 1994, 1209(1), 130-139.
17. Masferrer, J.L.; Zweifel, B.S.; Manning, P.T.; Hauser, S.D.; Leahy, K.M.; Smith, W.G.; Isakson, P.C.; Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 1994, 91(8), 3228-3232.
18. Johnson, J.L.; Wimsatt, J.; Buckel, S.D.; Dyer, R.D.; Maddipati, K.R. Purification and characterization of prostaglandin H synthase from sheep placental cotyledons. Arch. Biochem. Biophys., 1995, 324, 26-34.
19. Aguejouf, O.; Eizayaga, F.; Desplat, V.; Belon, P.; Doutremepuich, C. Pro-thrombotic and hemorrhagic effects of aspirin. Clin. Appl. Thromb. Hemost., 2009, 15(5), 523-528.
20. Doutremepuich, C.; Aguejouf, O.; Belon, P. Effects of ultra-low-dose aspirin on embolization in a model of laser-induced thrombus formation Semin. Thromb. Hemost., 1996, 22 Suppl 1,; 67-70.
21. Buerkle, M.A.; Lehrer, S.; Sohn, H.Y.; Conzen, P.; Pohl, U.; Krötz, F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation, 2004, 110(14), 2053-2059.
22. Eizayaga, F.X.; Aguejouf, O.; Desplat, V.; Belon, P.; Doutremepuich, C. Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose aspirin on platelet activity in portal hypertension. Pathophysiol. Haemost. Thromb. 2006, 35(5), 357-363.
23. Hong, T.T.; Huang, J.; Barrett, T.D.; Lucchesi, B.R. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(1), H145-55.
24. Doutremepuich, C.; Aguejouf, O.; Eizayaga, F.; Desplat, V. Reverse effect of aspirin: is the pro-thrombotic effect after aspirin discontinuation mediated by COX 2 blockade? Circulation, 2006, 114, II_73.
25. Lordkipanidzé, M.; Diodati, J.G.; Pharand, C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. Pharmacol. Therapeutics, 2009, doi: 10.1016/ j.pharmthera.2009.03.019 (Epub ahead of print).